Scientific Program

Saturday, August 3

1-5pm Registration/Poster Set-up

Sunday, August 4

8am-5pm Registration
8:15am Welcome and Introduction – Carol Black and Robert Lafyatis

Session 1 – Integrative Medicine

8:25am Introduction
8:30 The application of bioinformatics to autoimmune disease – Atul Butte
9:30 The genetic basis for tsk2 – Elizabeth Blankenhorn
10:00 Discussion
10:30 COFFEE BREAK

Session 2 – Biomarkers

10:55 Introduction
11:00 Biomarkers of interstitial lung disease – Naftali Kaminski
11:30 Alterations in angiogenesis in systemic sclerosis – Marco Matucci Cerinic
12:00pm Discussion
12:30 LUNCH

Session 3 – ER Stress

1:55 Introduction
2:00 Unfolded protein response and oxidative stress – Randal Kaufman
2:30 Mechanotransduction and redox regulation in lung fibrosis - Victor Thannickal
3:00 Discussion
3:30 TEA BREAK

Session 4 – Environmental & Infectious Disease Triggers

3:55 Introduction
4:00 Identifying environmental factors in autoimmune diseases – Fred Miller
4:30 Microbial pathogens in skin disease – Sarah Arron
5:00 Discussion
5:30 END of SESSION
5:45 WELCOME RECEPTION –  AGGANIS ARENA

Monday, August 5

Session 5 – Molecular Genetics and Fibrosis

7:55am Introduction
8:00 Non-coding RNAs in skin – Howard Chang
8:30 Epigenetics and liver fibrosis – Derek Mann
9:00 Discussion

Session 6 – High Throughput Proteomics

9:15 Introduction
9:20 Systems-level analysis of proteolytic events in increased vascular permeability
and complement activation in skin inflammation- Chris Overall
9:50 Biomarker studies in lupus nephritis – Chandra Mohan
10:20 Discussion
10:35 COFFEE BREAK

Session 7 – Matrisomal Proteins and Adipose in Fibrosis

10:55 Introduction
11:00 Decoding the matrix – Richard Hynes
11:30 Advances in understanding adipogenesis and links to fibrosis – Stephen Farmer
12:00pm Discussion
12:15 LUNCH

Session 8 – Angiogenesis & Pericytes

1:25 Introduction
1:30 Pericytes – Annika Keller
2:00 Mesenchymal cells and pericytes in lymph node architecture – Theresa Lu
2:30 Pericytes in injury and fibrosis – Lucie Peduto
3:00 Discussion
3:15 TEA BREAK

Session 9 – Vascular Disease – Applications to Scleroderma

3:40 Introduction
3:45 Pathophysiology of giant cell arteritis – Cornelia Weyand
4:00 Vascular capillary leak in systemic sclerosis – Tracy Frech
4:15 Biomarkers of vasculitis – Paul Monach
4:30 Discussion
5:00 END of SESSION

Tuesday, August 6

Session 10 -Breakthroughs in Therapy

7:55am Introduction
8am Autologous hematopoietic stem cell treatment of scleroderma
– lessons learned over 15 years - Alan Tyndall

Session 11 – PAH & Vascular Remodeling

8:40am Introduction
8:45 Cell therapy approaches for pulmonary arterial hypertension – Duncan Stewart
9:15 Inflammation and hypoxia in pulmonary arterial hypertension – Kurt Stenmark
9:45 Discussion
10:15 COFFEE BREAK

Session 12 – Industry Presentations

10:40 Introduction
10:45 Evaluation of the anti-fibrotic properties of CCNs in pulmonary fibrosis -
R Lemaire – Medimmune
11:00 TLR blockade in autoimmune disease – R Arbeit – Idera
11:15 Dasatinib in systemic sclerosis – B Ganguly – Bristol Myers Squibb
11:30 Pharmaceutical development of anti-fibrotic medicines for the 21st
Century: Enhancing our chances of success - D Budd – GlaxoSmithKline
11:45 Molecular diagnostics for systemic sclerosis:  Towards
personalized medicine – Y Nesbeth – Celdara
12:00pm LUNCH

Session 13 – Selected Abstract Presentations

1:25 Introduction
1:30 Interleukin-33 is an upstream regulator of inflammation
and fibrosis - Irina Luzina
1:45 RNA-seq and miR-seq analysis of SSc skin across intrinsic gene
expression subsets shows differential expression of non-coding
RNAs regulating SSc gene expression - Zhenghui Li
2:00 Ephrin B2 is overexpressed in human scleroderma skin and
mediates fibroblast to myofibroblast differentiations, and
induces fibrosis in mice – David Lagares
2:15 SSc intrinsic subset classification in patients that demonstrate
clinical improvement during treatment – Monique Hinchcliff
2:30 JNK-1 shows an association with systemic sclerosis - Sandra Guerra
2:45 Pulmonary hypertension in patients with U1-RNP antibodies
- Vincent Sobanski

3 – 5 pm – Poster Viewing ~ 18th Floor Lounge ~ 10 Buick Street

6pm – BANQUET – Metcalf Trustee Center Ballroom ~ One Silber Way ~ 9th Floor

Banquet Speaker:  Joseph Loscalzo, MD, PhD, Chairman, Department of Medicine; Physician-in-Chief; Brigham and Women’s Hospital; Hersey Professor of the Theory and Practice of Medicine, Harvard Medical School

Wednesday, August 7

Session 14 – Innate Inflammation in Fibrosis I

7:55am Introduction
8:00 The inflammasome in interstitial lung disease – Augustine Choi
8:30 Lipid mediators in inflammation and fibrosis – Charles Serhan

Session 15 – Innate Inflammation in Fibrosis II

9:00 Sterile injury and inflammation – Richard Flavell
9:30 Inflammasomes in systemic sclerosis – Carol Artlett
10:00 Discussion
10:30 COFFEE BREAK

Session 16 – Monocytes/Macrophages in Fibrotic Disease

10:55 Introduction
11:00 Macrophage heterogeneity and alternative activation – Siamon Gordon
11:30 Macrophage activation in fibrosis – Tom Wynn
12:00pm Discussion
12:15 LUNCH

1:15 – Meeting – SCAR & SScores

Session 17 – Scleroderma Clinical Trials Consortium

2:15 Introduction
Should there be a paradigm shift in clinical trials for SSc?
2:20 CRISS protocol – P Merkel
2:30 Case selection for stem cell transplantation in systemic sclerosis – C Denton 

Discussion:  L Chung

Biomarkers and patient samples – Moderator:  M Mayes
3:00 Use of biomarkers as outcome measures – R Lafyatis
3:10 Control of patient samples from clinical trials – R Simms 

Discussion:  M Mayes

Use of observational cohorts in clinical trials – Moderator:  V Steen
3:40 ESOS study – A Herrick
3:50 Statistical challenges of observational trials – S Johnson
4:00 Discussion – V Steen

END of WORKSHOP